These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 23091101)

  • 1. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
    Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B
    J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
    Gisselbrecht C; Glass B; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Ketterer N; Shpilberg O; Hagberg H; Ma D; Brière J; Moskowitz CH; Schmitz N
    J Clin Oncol; 2010 Sep; 28(27):4184-90. PubMed ID: 20660832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation.
    Calvo-Villas JM; Martín A; Conde E; Pascual A; Heras I; Varela R; de la Rubia J; Ramirez MJ; Díez-Martín JL; Panizo C; Rodríguez-Salazar MJ; Pascual MJ; Donato EM; González-Barca E; Caballero MD;
    Ann Oncol; 2010 Sep; 21(9):1891-1897. PubMed ID: 20231299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
    Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
    Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.
    Haioun C; Mounier N; Emile JF; Ranta D; Coiffier B; Tilly H; Récher C; Fermé C; Gabarre J; Herbrecht R; Morchhauser F; Gisselbrecht C
    Ann Oncol; 2009 Dec; 20(12):1985-92. PubMed ID: 19567453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
    Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
    Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
    Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
    Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
    van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
    J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
    Hagberg H; Gisselbrecht C;
    Ann Oncol; 2006 May; 17 Suppl 4():iv31-2. PubMed ID: 16702182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Ohmachi K; Niitsu N; Uchida T; Kim SJ; Ando K; Takahashi N; Takahashi N; Uike N; Eom HS; Chae YS; Terauchi T; Tateishi U; Tatsumi M; Kim WS; Tobinai K; Suh C; Ogura M
    J Clin Oncol; 2013 Jun; 31(17):2103-9. PubMed ID: 23650408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
    Kewalramani T; Zelenetz AD; Nimer SD; Portlock C; Straus D; Noy A; O'Connor O; Filippa DA; Teruya-Feldstein J; Gencarelli A; Qin J; Waxman A; Yahalom J; Moskowitz CH
    Blood; 2004 May; 103(10):3684-8. PubMed ID: 14739217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy.
    Tun AM; Wang Y; Maliske S; Micallef I; Inwards DJ; Habermann TM; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
    Transplant Cell Ther; 2024 Oct; 30(10):1001.e1-1001.e12. PubMed ID: 38996973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
    Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
    Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
    Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM
    Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.
    Armand P; Welch S; Kim HT; LaCasce AS; Jacobsen ED; Davids MS; Jacobson C; Fisher DC; Brown JR; Coughlin E; Freedman AS; Chen YB
    Br J Haematol; 2013 Mar; 160(5):608-17. PubMed ID: 23278720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.